A share price of C4 Therapeutics Inc [CCCC] is currently trading at $1.54, down -4.35%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CCCC shares have gain 23.20% over the last week, with a monthly amount drifted -16.76%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
C4 Therapeutics Inc [NASDAQ: CCCC] stock has seen the most recent analyst activity on December 19, 2024, when Wells Fargo upgraded its rating to a Overweight and also boosted its price target to $12 from $8. Previously, Stephens started tracking the stock with Equal-Weight rating on November 18, 2024, and set its price target to $4. On January 29, 2024, upgrade upgraded it’s rating to Neutral but maintained its price target of $6 on the stock. Stifel upgraded its rating to a Buy and increased its price target to $12 on December 13, 2023. Credit Suisse upgraded its rating to a Neutral and reduced its price target to $10 on February 24, 2023. JP Morgan downgraded its rating to Underweight for this stock on February 24, 2023, and downed its price target to $5. In a note dated November 04, 2022, JP Morgan downgraded an Neutral rating on this stock and revised its target price from $22 to $15.
C4 Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $1.09 and $7.66. Currently, Wall Street analysts expect the stock to reach $12 within the next 12 months. C4 Therapeutics Inc [NASDAQ: CCCC] shares were valued at $1.54 at the most recent close of the market. An investor can expect a potential return of 679.22% based on the average CCCC price forecast.
Analyzing the CCCC fundamentals
Trailing Twelve Months sales for C4 Therapeutics Inc [NASDAQ:CCCC] were 35.58M which represents 58.75% growth. Gross Profit Margin for this corporation currently stands at 0.83% with Operating Profit Margin at -3.36%, Pretax Profit Margin comes in at -2.96%, and Net Profit Margin reading is -2.96%. To continue investigating profitability, this company’s Return on Assets is posted at -0.3, Equity is -0.44 and Total Capital is -0.39. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.3.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.4746 points at the first support level, and at 1.4093 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.6207, and for the 2nd resistance point, it is at 1.7015.
Ratios To Look Out For
To put it in perspective, the Current Ratio for C4 Therapeutics Inc [NASDAQ:CCCC] is 5.71. In addition, the Quick Ratio stands at 5.71 and the Cash Ratio stands at 1.23. Considering the valuation of this stock, the price to sales ratio is 3.07, the price to book ratio is 0.50.
Transactions by insiders
Recent insider trading involved Boyle Scott N, Chief Business Officer, that happened on Feb 18 ’25 when 669.0 shares were sold. Chief Business Officer, Boyle Scott N completed a deal on Feb 14 ’25 to sell 490.0 shares. Meanwhile, Director Salter Malcolm bought 13000.0 shares on Nov 18 ’24.
